



ASX Announcement/Press Release | 26 March 2025 AdAlta Limited (ASX:1AD)

AdAlta to present at TSN ASX Emerging Gems Conference

AdAlta Limited (ASX:1AD) (“AdAlta” or “the Company”), developer of next generation cell and protein therapeutic products is presenting at The Stock Network’s next Emerging ASX Gems Investment Conference, which is being held on 28 March 2025 (commencing at 11.00AM AEDT).

In his presentation, AdAlta’s CEO and Managing Director, Dr Tim Oldham will explain to conference attendees:

- The growth upside in AdAlta’s “East to West” strategy, which is seeing the company’s AdCella business build a portfolio of Asia-sourced cellular immunotherapy assets targeting solid cancers
- The opportunity for the AdCella business to accept external funding
- How AdAlta is working to monetise the value of its inhouse developed fibrotic disease drug candidate AD-214.

Investors can register for this Emerging ASX Gems Investment Conference by clicking on the following link and follow the prompts:

<https://www.eventbrite.com/e/the-stock-networks-asx-gems-conference-tickets-1298761062299?aff=oddtcreator>

To engage in discussion or view a replay of the presentation (to be posted after the event) visit AdAlta’s InvestorHub here: <https://investorhub.adalta.com.au/link/MrD9oP>

This ASX announcement has been authorised for release by the CEO of AdAlta Limited (ASX:1AD).

For further information, please contact:

AdAlta Limited (ASX:1AD)

Tim Oldham
CEO & Managing Director
P: +61 3 9479 5159
E: t.oldham@adalta.com.au

Media & Investor Enquiries

The Capital Network
Julia Maguire
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About AdAlta

AdAlta (ASX: 1AD) is a clinical stage biotechnology business addressing the need for effective cellular immunotherapies for the treatment of solid cancers.

Through its ‘East to West’ strategy, the Company is integrating Asia’s prowess in T cell therapy development with the efficiency and quality of Australia’s clinical and manufacturing ecosystem to create a pathway connecting ‘Eastern’ innovation in cellular immunotherapies with ‘Western’ regulated markets and patients.

AdAlta in-licenses products from Asian originators and invests to establish US FDA regulated manufacturing and conduct Phase I clinical studies with potential to position each product for on-licensing to larger biopharmaceutical companies for potential registrational studies and commercialization.

AdAlta implements a disciplined approach to asset selection focused on highly differentiated T cell therapy products supported by clinical data in solid cancers. The company adopts a capital efficient business model delivering a rapid return on investment in each project that is replicable and provides opportunities to scale across multiple products.

Solid tumours account for 90% of cancers yet remain underserved by current cellular immunotherapies. AdAlta aims to dominate this high-growth segment. The cellular immunotherapy market is projected to grow at a compound annual growth rate of 34% to reach US\$20.3 billion by 2028.

AdAlta's first in class fusion protein, AD-214, takes a whole new approach to fibrotic diseases of the lung and kidney, such as the degenerative and fatal Idiopathic Pulmonary Fibrosis. Following demonstration of efficacy in multiple animal models of disease and two successful Phase I clinical studies, AD-214 is available for partnering.

To learn more, please visit: www.adalta.com.au

For more information



Join our [InvestorHub](#)



Follow us on [LinkedIn](#)



Follow us on [X \(formerly Twitter\)](#)